PDGFRA and neoplasm: T aptamers that specifically recognize PDGFRα and PDGFRβ, respectively, to deliver anti-miR-222, miR-137, and anti-miR-10 b to glioblastoma cells, achieving receptor-dependent selective modulation of endogenous miRNA levels, increased sensitivity to temozolomide, and inhibition of tumor growth and migration both in vitro and in vivo [4].